When a Game Becomes a Prescription: What Cognitive Digital Therapeutics Are Really Doing

If you or a family member have ever played a "brain training" game on your phone, you probably thought of it as nothing more than a way to pass the time. But at one hospital, a 59-year-old woman received something unexpected from her doctor: a prescription that was, quite literally, a game app. She was instructed to complete specific game tasks on her phone every day, just as she would take a pill on schedule. It sounds novel—even counterintuitive. Can playing a game really treat an illness?

The answer is yes—though what it treats isn't a cold or the flu, but a far more formidable enemy: Alzheimer's disease and its precursor stages.

Among people aged 60 and older worldwide, tens of thousands live with cognitive impairment, and more than half of them have mild cognitive impairment. Mild cognitive impairment is a critical window between normal aging and dementia. Without intervention, roughly 10% to 15% of people with mild cognitive impairment slide into Alzheimer's disease each year—a progression currently considered irreversible. Faced with such a vast population and limited pharmacological options, the medical community has turned its attention to a field that hardly seems glamorous: digital therapeutics.

What fundamentally separates these tools from ordinary brain-training games is the word "evidence."

The match-three games or Sudoku apps you download from an app store were designed for entertainment. They haven't been validated in rigorous clinical trials, and they aren't regulated as medical devices. A cognitive digital therapeutic prescribed as a "prescription," by contrast, is essentially a medical device in software form. Take the training app approved in China: it holds a Class II medical device registration certificate, meaning its safety and efficacy have been reviewed by the drug regulatory authority. Its design is grounded in the six cognitive domains outlined in cognitive psychology and the diagnostic manual of mental disorders—perceptual-motor function, executive function, language, memory, attention, and social cognition. The game is merely the shell; the core is graded, repetitive training targeted at specific impaired brain regions.

The scientific assumption behind this is called neuroplasticity. The brain is not a fixed circuit board. Even amid aging or disease, specific, targeted stimulation can still activate and strengthen surviving neural connections. Put simply, when the pathways carrying information in the brain become blocked or overgrown, training is the work of "repaving the road" so signals can flow again.

So does this "road repair" actually work? Research data offer cautiously optimistic footnotes. A meta-analysis pooling multiple randomized controlled trials found that digital cognitive stimulation therapy produced a statistically significant improvement in cognitive function among dementia patients, with a pooled effect size that was small to moderate (SMD 0.33). More intriguingly, when researchers focused on mobile applications as the delivery vehicle, the effect became more pronounced (SMD 0.64). This suggests that putting training into phones and tablets—making it accessible anytime, anywhere—may be more effective than having patients sit at a computer completing tedious tasks. At the very least, from a compliance standpoint, gamified packaging lowers the threshold for sticking with it [1].

None of this means we should simply download a few brain games and start "self-treating." The prescription status of digital therapeutics makes them a serious matter. In a proper clinical workflow, a doctor first uses standardized scales to assess where a patient falls: normal aging, subjective cognitive decline, or mild cognitive impairment. Only patients with a confirmed diagnosis of mild cognitive impairment are appropriate candidates for this kind of training. The software dynamically adjusts difficulty based on each click, reaction time, and accuracy rate, keeping the training perpetually in the "just beyond reach" zone—too easy is boring, too hard is discouraging, and either one leads to abandonment.

What's more telling is that exploration of digital therapeutics in Alzheimer's disease has long moved beyond the single dimension of "cognitive training." A clinical trial registration in Europe shows that an app called Cogthera is testing a multimodal intervention: it bundles cognitive training, physical activity under dual-task conditions, meditation audio, and even educational content into a single package, delivered as an add-on to standard care, to see whether it can improve cognitive performance in people with mild cognitive impairment or mild Alzheimer's disease within 12 weeks. This hints at a trend: the "game prescription" of the future may no longer be a single set of memory flashcards, but a digital package integrating movement, relaxation, and social elements.

Of course, we must remain clear-eyed. Digital therapeutics are not a magic wand that cures Alzheimer's disease; they cannot even guarantee that progression will be halted. High-quality research still suffers from high heterogeneity and limited sample sizes, and some trial results are inconsistent. They are better understood as an active defense in a pharmacological void. When no wonder drug can reverse cognitive decline, the most pragmatic thing we can do is harness the brain's residual plasticity to preserve function for as long as possible and delay the arrival of that "cliff edge" [2].

For patients and families alike, understanding the boundaries of cognitive digital therapeutics is just as important. They cannot replace social interaction, they cannot replace a walk, and they certainly cannot replace managing blood pressure and blood sugar—the basic elements of vascular risk management. But they do offer a structured, quantifiable, sustainable daily anchor. In the past, a doctor could only advise "keep your brain active." Now that advice becomes a concrete task: 20 minutes a day, four modules of games, with data uploaded automatically so the doctor can see in the back end whether you practiced and how you did.

This may be the most unassuming value of digital therapeutics: turning a vague piece of medical advice into something you can actually do. As the 59-year-old woman earnestly "plays" a game about organizing kitchen utensils on her phone, something invisible is happening in her brain. The neural connections that the disease is trying to sever may, through repeated and engaging stimulation, be striving to reconnect.

[1]Saragih ID, et al. Efficacy of digital cognitive stimulation therapy for people with dementia: a systematic review and meta-analysis. BMC Geriatr. 2026 Apr 6;26(1):700. doi: 10.1186/s12877-026-07180-9. PMID: 41942923; PMCID: PMC13191879.

https://pmc.ncbi.nlm.nih.gov/articles/PMC13191879/#3

[2]Tran DK, Hu CJ, Kuan YC. Digital reminiscence therapy in dementia care: a systematic review and meta-analysis. BMC Neurol. 2026 Mar 25;26(1):296. doi: 10.1186/s12883-026-04759-y. PMID: 41882555; PMCID: PMC13137691.

https://pmc.ncbi.nlm.nih.gov/articles/PMC13137691/#3